The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom

被引：0
|
作者：
Greystoke, A. [1 ]
Carter, M. [2 ]
Griffiths, W. [1 ]
Laviste, G. [2 ]
Ortega-Franco, A. [2 ]
Rafee, S. [2 ]
Hannaway, N. [1 ]
Bridgewood, A. [1 ]
Hall, S. [1 ]
Blackhall, F. H. [2 ]
机构：
[1] Freeman Hosp NHS Fdn Trust Northern Ctr Canc Care, Med Oncol Dept, Newcastle Upon Tyne, Tyne & Wear, England
[2] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1337P
引用
收藏
页码：S859 / S859
页数：1
相关论文
共 50 条
  • [1] KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
    Garzon, Monica
    Villatoro, Sergi
    Teixido, Cristina
    Mayo, Clara
    Martinez, Alejandro
    Llanos Gil, Maria de Los
    Viteri, Santiago
    Morales-Espinosa, Daniela
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 511 - 516
  • [2] The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Grinberg, R.
    Roisman, L.
    Geva, S.
    Lefterova, M.
    Quinn, K.
    Gutman, L. Soussan
    Dvir, A.
    Yair, R.
    Twito, T.
    Lanman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S925 - S926
  • [3] The influence of circulating tumor DNA analysis on response to immunotherapy in non-small cell lung cancer (NSCLC)
    Grinberg, R.
    Roisman, L. C.
    Geva, S.
    Soussan-Gutman, L.
    Dvir, A.
    Yair, R.
    Twito, T.
    Larman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S35 - S36
  • [4] Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
    Herbreteau, Guillaume
    Vallee, Audrey
    Charpentier, Sandrine
    Normanno, Nicola
    Hofman, Paul
    Denis, Marc G.
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S113 - S126
  • [5] The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).
    Genova, Carlo
    Truini, Anna
    Rijavec, Erika
    Barletta, Giulia
    Biello, Federica
    Dal Bello, Maria Giovanna
    Coco, Simona
    Alama, Angela
    Vanni, Irene
    Grossi, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
    Fernandes, Maria Gabriela O.
    Cruz-Martins, Natalia
    Machado, Jose Carlos
    Costa, Jose Luis
    Hespanhol, Venceslau
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [7] The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
    Maria Gabriela O. Fernandes
    Natália Cruz-Martins
    José Carlos Machado
    José Luís Costa
    Venceslau Hespanhol
    Cancer Cell International, 21
  • [8] Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer
    Morgensztern, Daniel
    Devarakonda, Siddhartha
    Masood, Ashiq
    Waqar, Saiama
    Carmack, Alicia
    Banks, Kimberly
    Lanman, Richard
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S717 - S718
  • [9] Detection of EGFR Mutations in Circulating Cell-Free DNA (cfDNA) from Plasma Samples of Patients with Non-Small Cell Lung Cancer Using the Oncomine Lung cfDNA Assay
    Anand, S.
    Matharu, B.
    Lu, W.
    Dimastrogiovanni, D.
    Butler, C.
    Verrissimo, T.
    Harden, S.
    Gilligan, D.
    Jones, A.
    Scott, M.
    Liu, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S18 - S19
  • [10] A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA
    Wei, Lirong
    Wu, Wangxi
    Han, Liming
    Yu, Weimo
    Du, Yuzhen
    ONCOLOGY LETTERS, 2018, 16 (04) : 4353 - 4360
12345